… The importance of EGFR to lung cancers supports the concept of ‘oncogene addiction’.
Tyrosine kinase inhibitors (TKIs) have been used to treat the cancer harboring EGFR mutations …

… In the updated result of BR.21, EGFR FISH + patients had significantly higher RR than FISH
- patients (21 vs 5%; p = 0.02). Moreover, survival benefit of erlotinib was seen in patients …

… tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, and the second-generation
EGFR… -line treatments for advanced EGFR-mutant non-small cell lung cancer (NSCLC) based …

… EGFR exon19del or L858R-mutant lung cancers treated with first/second-generation EGFR
tyrosine kinase … EGFR wild-type lung adenocarcinoma samples were used for comparison. …

… Third generation EGFR TKIs, such as Osimertinib, are … -cell lung cancer who has undergone
EGFR targeted therapy and … be a sensitising mutation to EGFR tyrosine kinase inhibitors. …

… cancers than in those with non-oncogene-driven cancers. This … related cancers than in EGFR
mutation-positive driven cancers… EGFR mutation-positive NSCLC remains yet to be proven. …

… (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell lung
cancer (NSCLC) with sensitizing EGFR … -naïve patients with EGFR mutant NSCLC, osimertinib …

… EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present
an update … This article reviews the clinical implications of EGFR mutations in lung cancer …

… (EGFR) tyrosine kinase inhibitors (TKIs) in patients with EGFR mutation-positive non-small
cell lung cancer (… patients with tumors harboring common EGFR mutations (exon 19 deletions […

… Hence, we performed a systematic review and meta-analysis to provide an update and to
summarize the efficacy and safety of EGFR-TKIs combined with chemotherapy or …